Global Leading Market Research Publisher QYResearch announces the release of its latest report “Cancer Companion Diagnostic – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Cancer Companion Diagnostic market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Cancer Companion Diagnostic was estimated to be worth US3.5billionin2025andisprojectedtoreachUS3.5billionin2025andisprojectedtoreachUS 9.2 billion by 2032, growing at a CAGR of 14.8% from 2026 to 2032.
For oncologists, pathologists, and precision medicine program directors, the core diagnostic challenge is precise: identifying predictive biomarkers (EGFR mutations, ALK rearrangements, ROS1, KRAS, BRAF V600E, HER2 overexpression/amplification, BRCA1/2, PD-L1 expression, MSI-H/dMMR, NTRK fusions, RET, MET, FGFR) from tumor tissue (FFPE, biopsy, resection) or liquid biopsy (plasma circulating tumor DNA (ctDNA)) to match patients with targeted therapies (gefitinib, osimertinib, crizotinib, entrectinib, trastuzumab, pembrolizumab) or immunotherapies (checkpoint inhibitors), selecting those most likely to respond (exclude non-responders, avoid unnecessary toxicity, reduce healthcare costs), supporting regulatory approval (FDA/EMA co-developed test with drug), and enabling fast turnaround (2-5 days for PCR, 7-14 days for NGS) for treatment initiation. The solution lies in cancer companion diagnostics (CDx)—FDA-approved or CE-marked in vitro diagnostic (IVD) tests using tissue or blood, based on polymerase chain reaction (PCR, real-time qPCR, digital PCR), next-generation sequencing (NGS, targeted panel, whole exome, whole transcriptome), immunohistochemistry (IHC, protein expression), or fluorescence in situ hybridization (FISH, gene amplification/translocation). Unlike broad tumor profiling (research use only (RUO)), CDx tests are co-developed with specific drugs (theragnostic pair) and validated for clinical use (sensitivity/specificity, PPV/NPV). As targeted therapy approvals accelerate (immuno-oncology, antibody-drug conjugates (ADCs), PARP inhibitors, kinase inhibitors, RAS inhibitors) and drug labels require biomarker testing, the cancer CDx market grows.
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient’s therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis and reducing health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984769/cancer-companion-diagnostic
1. Industry Segmentation by Technology and Cancer Type
The Cancer Companion Diagnostic market is segmented as below by Type:
- Polymerase Chain Reaction (PCR) – 38% market share (2025). qPCR (quantitative), dPCR (droplet digital). Low cost, rapid turnaround (1-3 days), high sensitivity (0.1-1% mutant allele fraction (MAF)). For single/multiplex (EGFR, KRAS, BRAF, ALK fusions via RT-PCR).
- Next-Generation Sequencing (NGS) – 32% market share, fastest-growing at 18% CAGR. Targeted panels (50-500 genes, 0.5-5% MAF). Comprehensive (single test for all guidelines). Higher cost, longer TAT (7-14 days). For multi-biomarker, rare variants.
- Immunohistochemistry (IHC) – 18% market share (protein expression). PD-L1 (22C3, 28-8, SP142, SP263), HER2 (ERBB2), ALK (D5F3). Automated, rapid (1 day), but semi-quantitative (pathologist scoring).
- Fluorescence In Situ Hybridization (FISH) – 12% market share (gene amplification, fusion, translocation). HER2, ALK, ROS1, MET, NTRK. Labor-intensive, costly, declining replaced by NGS.
By Application – Lung Cancer (NSCLC, EGFR, ALK, ROS1, MET, RET, KRAS G12C, PD-L1) leads with 34% market share. Breast Cancer (HER2, hormone receptors (ER/PR), BRCA1/2, PIK3CA) 28% share. Colorectal Cancer (KRAS/NRAS/BRAF, MSI, HER2) 18% share. Others (melanoma (BRAF), gastric (HER2), prostate (BRCA), ovarian (BRCA), GIST (KIT, PDGFRA)) 20% share.
Key Players – Global CDx developers: Roche (Foundation Medicine, tissue-based NGS CDx, VENTANA IHC), Illumina (TruSight Oncology, NGS), Thermo Fisher (Oncomine Dx Target, NGS), Qiagen (therascreen PCR kits), Agilent (Dako IHC, PD-L1), Abbott (FISH, Vysis), Guardant Health (liquid biopsy Guardant360 CDx), AmoyDx (China, PCR CDx), Novogene (NGS). Also: Myriad Genetics (BRACAnalysis), Exact Sciences (Oncotype DX), Biocartis (Idylla), Invivoscribe (LeukoStrat).
2. Technical Challenges: Tissue Sample Quality, Turnaround Time, Reimbursement
FFPE tissue degradation — Formalin-fixed, paraffin-embedded (FFPE) samples crosslink nucleic acids (DNA, RNA), fragmentation. NGS library prep optimization (FFPE repair, UDG (uracil-DNA glycosylase)). PCR fragment size <150 bp.
Turnaround time (TAT) — For treatment initiation (advanced cancer, aggressive disease), TAT <7 days desired. PCR (2-3 days), NGS (7-14 days). Liquid biopsy (ctDNA) faster (no tissue biopsy delay).
Reimbursement and coverage — Medicare/ private insurance covers NGS (FDA-approved CDx). High complexity lab validation.
3. Policy, User Cases & Market Trends (Last 6 Months, 2025-2026)
- FDA Guidance (2025) (Companion Diagnostic Co-development) – Drug and test co-approved (simultaneous submission).
- CMS (Centers for Medicare & Medicaid Services) NCD (National Coverage Determination) (2026) – Covers NGS for solid tumors.
- China NMPA (2026) (National Medical Products Administration) – CDx for PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, sintilimab, camrelizumab). IHC kits approved.
User Case – NSCLC (non-small cell lung cancer) EGFR testing — PCR (cobas, therascreen) detects exon 19 deletion (del19), L858R, T790M resistance. Osimertinib (Tagrisso) indicated. Liquid biopsy (Guardant360) for T790M after progression.
User Case – Breast cancer HER2 (ERBB2) testing — IHC (HercepTest, Pathway) score 3+ (positive) or equivocal (2+) reflex to FISH or NGS (HER2 amplification ratio >2.0). Trastuzumab (Herceptin) for HER2+.
4. Exclusive Observation: Liquid Biopsy CDx
Plasma ctDNA CDx (Guardant360, FoundationOne Liquid, Resolution Bio) companion to targeted therapy for advanced cancer when tissue insufficient. FDA-approved for EGFR, BRAF, KRAS G12C. Not for primary diagnosis.
5. Outlook & Strategic Implications (2026-2032)
Through 2032, the cancer CDx market will segment: PCR (single-biomarker) — 30% value, 10-11% CAGR; NGS (comprehensive genomic profiling) — 48% value, 17-18% CAGR; IHC (protein expression) — 12% value, 9-10% CAGR; liquid biopsy (ctDNA) — 10% value, 20% CAGR. Key success factors: FDA/CE-IVD (in vitro diagnostic) approval, co-development with pharma, turn-around time (<7 days), and Medicare/ private coverage. Suppliers who fail to transition from RUO to IVD CDx — and who cannot validate NGS panels for all guideline biomarkers — will lose precision oncology market share.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
